Precision BioSciences to Report First Quarter Results on May 13, 2024
2024年5月8日 - 5:30AM
ビジネスワイヤ(英語)
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene
editing company utilizing its novel proprietary ARCUS® platform to
develop in vivo gene editing therapies for sophisticated gene
edits, including gene elimination, insertion, and excision, today
announced that it will publish financial results for the first
quarter 2024 and provide a business update on Monday, May 13,
2024.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company
dedicated to improving life (DTIL) with its novel and proprietary
ARCUS® genome editing platform that differs from other technologies
in the way it cuts, its smaller size, and its simpler structure.
Key capabilities and differentiating characteristics may enable
ARCUS nucleases to drive more intended, defined therapeutic
outcomes. Using ARCUS, the Company’s pipeline is comprised of in
vivo gene editing candidates designed to deliver lasting cures for
the broadest range of genetic and infectious diseases where no
adequate treatments exist. For more information about Precision
BioSciences, please visit www.precisionbiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240507972330/en/
Investor and Media Contact: Naresh Tanna Vice President
of Investor Relations naresh.tanna@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
過去 株価チャート
から 4 2024 まで 5 2024
Precision BioSciences (NASDAQ:DTIL)
過去 株価チャート
から 5 2023 まで 5 2024